Stimulant Use Disorder
18
7
8
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
5.6%
1 terminated out of 18 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (18)
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails
reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)
RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)
LDART for Stimulant Use Disorder
Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study
Repetitive Transcranial Magnetic Stimulation Treatment of Stimulant Use Disorder
Optimizing Transcranial Magnetic Stimulation for Stimulant Use Disorder
Suvorexant for Opioid/Stimulant Co-use
Continuum of Care in Hospitalized Patients With Opioid/Stimulant Use Disorder and Infectious Complications From Drug Use
Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder
Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation
Smartphone Services for Stimulant Use Disorder
rTMS for Stimulant Use Disorders
PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study